Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market.
The listing, which aims to raise approximately 90 billion Korean Won ($67 million) from the sale of three million shares, comes at a time when South Korea's biotech industry is experiencing rapid growth.
Backed by initiatives like the government's Bio Economy 2.0, the country is positioning itself as a leader in biologics and biosimilars, with major companies like Samsung Biologics (KRX: 207940) and Celltrion (KRX: 068270) driving innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze